곧창자 샘암종에서 EGFR 과발현과 수술 전 방사선화학 치료 반응
Epidermal Growth Factor Receptor Overexpression and the Tumor Response to Preoperative Radiochemotherapy for Patients with Advanced Rectal Cancer
유진영, 이교영, 강석진, 정지한, 최현주, 정주원,
소속 상세정보
유진영 ( Yoo Jin-Young )
가톨릭대학교 의과대학 병리학교실
이교영 ( Lee Kyo-Young )
가톨릭대학교 의과대학 병리학교실
강석진 ( Kang Seok-Jin )
가톨릭대학교 의과대학 병리학교실
정지한 ( Jung Ji-Han )
가톨릭대학교 의과대학 병리학교실
최현주 ( Choi Hyun-Joo )
가톨릭대학교 의과대학 임상병리학교실
정주원 ( Chyung Ju-Won )
가톨릭대학교 의과대학 병리학교실
KMID : 0357920070410050316
Abstract
Background : An association between the epidermal growth factor receptor (EGFR) signaling pathway and the response of cancer cells to ionizing radiation has been previously des- cribed. Preoperative radiochemotherapy (PRCT) has been administered for treating locally advanced rectal cancer to improve the outcomes, and to preserve the sphincter from low-lying tumor. However, the responses of tumors to PRCT are variable and there are currently no reliable markers that predict the therapeutic benefits. We studied the association between EGFR overexpression and the tumor response to PRCT in rectal cancer.
Methods : The EGFR protein expression, as determined by immunohistochemistry, was analyzed in the pretreatment biopsy specimens from 120 patients with advanced rectal cancer. The tumor response was graded in the surgically resected specimens by using a three-scale grading system: no response (NR), partial remission (PR) and complete remission (CR).
Results : NR was identified in 70 cases (58.3%). Fifty patients (41.7%) responded to PRCT; 27 (22.5%) achieved a PR and 23 (19.2%) achieved a CR. EGFR overexpression was detected in 78 (65%) cases. Seventy-eight percent (39/50) of the tumors with a CR/PR revealed EGFR reactivity, whereas 55.7% (39/70) of the tumors with NR showed an EGFR expression (p=0.048).
Conclusions : The EGFR protein expression might be a valuable marker for identifying those patients who are most likely to benefit from PRCT
키워드
Rectal neoplasms;Gene;epidermal growth factor receptor
원문 및 링크아웃 정보
등재저널 정보